^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Excerpt:
...Tumors must stain positive for estrogen receptor (>= 10%) by immunohistochemistry (IHC)...
Trial ID:
Source:
Title:
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Excerpt:
Forty patients (20 OC and 20 EC) were enrolled. A PFS12 of 55% was observed in the EC cohort and 50% in the OC cohort. A PFS greater or equal to 24 weeks (PFS24) was seen in 20% (4/20) of the OC cohort and 35% (7/20) of the EC cohort….All three LGSOC patients obtained at least a partial response lasting for over 2 years, with two of the three patients still on treatment.
Secondary therapy:
letrozole
DOI:
10.1136/esmoopen-2020-000926.
Trial ID:
